/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Recent gene-profiling analyses showed significant upregulation of the folate hydrolase () gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8- to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent / GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in mice who exhibited resistance to DSS treatment. In the murine IL-10 model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of /GCPII enzymatic inhibition as a therapeutic option for IBD.